EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer

Kimberly Perez iD, Anna M Chiarella, James M Cleary, Nora Horick, Colin Weekes, Thomas Abrams, Lawrence Blaszkowsky, Peter Enzinger, Marios Giannakis, Lipika Goyal, Jeffrey A Meyerhardt, Douglas Rubinson und 14 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad002 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2023. Verfasst von Kimberly Perez und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Hypoalbuminemia, Pancreatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, AVEO Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In preclinical pancreatic ductal adenocarcinoma (PDAC) models, inhibition of hepatocyte growth factor (HGF) signaling using ficlatuzumab, a recombinant humanized anti-HGF antibody, and gemcitabine reduced tumor burden.

Methods

Patients with previously untreated metastatic PDAC enrolled in a phase Ib dose escalation study with 3 + 3 design of 2 dose cohorts of ficlatuzumab 10 and 20 mg/kg administered intravenously every other week with gemcitabine 1000 mg/m2 and albumin-bound paclitaxel 125 mg/m2 given 3 weeks on and 1 week off. This was followed by an expansion phase at the maximally tolerated dose of the combination.

Results

Twenty-six patients (sex, 12 male:14 female; median age, 68 years [range, 49-83 years]) were enrolled, 22 patients were evaluable. No dose–limiting toxicities were identified (N = 7 pts) and ficlatuzumab at 20 mg/kg was chosen as the maximum tolerated dose. Among the 21 patients treated at the MTD, best response by RECISTv1.1: 6 (29%) partial response, 12 (57%) stable disease, 1 (5%) progressive disease, and 2 (9%) not evaluable. Median progression-free survival and overall survival times were 11.0 months (95% CI, 7.6-11.4 months) and 16.2 months (95% CI, 9.1 months to not reached), respectively. Toxicities attributed to ficlatuzumab included hypoalbuminemia (grade 3, 16%; any grade, 52%) and edema (grade 3, 8%; any grade, 48%). Immunohistochemistry for c-Met pathway activation demonstrated higher tumor cell p-Met levels in patients who experienced response to therapy.

Conclusion

In this phase Ib trial, ficlatuzumab, gemcitabine, and albumin-bound paclitaxel were associated with durable treatment responses and increased rates of hypoalbuminemia and edema.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypoalbuminemiaPancreatic NeoplasmsHumansMaleFemaleAgedGemcitabineAlbumin-Bound PaclitaxelPaclitaxelAlbuminsEdemaAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal

Stichwörter der Autor:innen

nab-paclitaxelficlatuzumabgemcitabinemetastatic pancreatic cancerphase Ib clinical trial

Substanzen

GemcitabineAlbumin-Bound PaclitaxelPaclitaxelAlbumins130-nm albumin-bound paclitaxelficlatuzumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Harvard Medical School, Boston, MA, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
  • Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Division of Gastroenterology, Washington University School of Medicine, St. Louis, MO, USA.

ORCID-Profile: Kimberly Perez

Förderung

  • NCI NIH HHS
  • NIDDK NIH HHS
  • AVEO Pharmaceuticals

Zitieren

APA

Perez, K., Chiarella, A. M., Cleary, J. M., Horick, N., Weekes, C., Abrams, T., Blaszkowsky, L., Enzinger, P., Giannakis, M., Goyal, L., Meyerhardt, J. A., Rubinson, D., Yurgelun, M. B., Goessling, W., Giantonio, B. J., Brais, L., Germon, V., Stonely, D., Raghavan, S., …, & Wolpin, B. M. (2023). Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyad002

Vancouver

Perez K, Chiarella AM, Cleary JM, Horick N, Weekes C, Abrams T, et al. Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. The Oncologist. 2023. doi:10.1093/oncolo/oyad002

BibTeX
@article{Perez2023,
  author = {Perez, Kimberly and Chiarella, Anna M and Cleary, James M and Horick, Nora and Weekes, Colin and Abrams, Thomas and Blaszkowsky, Lawrence and Enzinger, Peter and Giannakis, Marios and Goyal, Lipika and Meyerhardt, Jeffrey A and Rubinson, Douglas and Yurgelun, Matthew B and Goessling, Wolfram and Giantonio, Bruce J and Brais, Lauren and Germon, Victoria and Stonely, Danielle and Raghavan, Srivatsan and Bakir, Basil and Das, Koushik and Pitarresi, Jason R and Aguirre, Andrew J and Needle, Michael and Rustgi, Anil K and Wolpin, Brian M},
  title = {Phase Ib and Expansion Study of Gemcitabine, Nab -Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad002}
}
Kostenlos starten →